SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy.

ABSTRACT:

Background

HIV cardiomyopathy (HIV-CM) is associated with significant morbidity and mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have benefits in heart failure (HF), but their role in the specialized population of HIV-CM is poorly understood.

Methods

Patients in the TriNetX Network with HIV-CM and SGLT2i therapy were compared to a propensity matched control group of patients with HIV-CM without SGLT2i use. The primary endpoint was all-cause mortality, secondary endpoints included all-cause hospitalizations, acute HF, stroke, acute myocardial infarction (MI), cardiac arrest, atrial fibrillation and ventricular tachycardia.

Results

In the total of 2606 included patients, SGLT2i therapy was associated with significant reduction in all-cause mortality (HR

SUBMITTER: Sheashaa H 

PROVIDER: S-EPMC12834926 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature